PolyPeptide Group AG (POLYPEPTIDE N) aktie

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, pharmaceutical, and biotech companies. PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.